Progyny, Inc. (PGNY): Results of Operations and Financial Condition
Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Progyny, Inc. Announces Second Quarter 2026 Results Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions V
How this was made
The 30-second read
Why it matters
Key disclosed items include record quarterly revenue, gross margin expansion, higher net income and adjusted EBITDA, a no-debt balance sheet, and continued share repurchases under an authorization.
Market read
Traders can update models immediately using the disclosed quarterly financials, margin trajectory, cash position, and the pace of share repurchases.
What to watch
Renewal risk is described as reduced for largest accounts, but the text also references a large non-renewing client in the prior year, so investors may focus on sustainability of client retention and utilization trends.
Background
This is Progyny’s SEC 8-K Item 2.02 with an attached earnings release (EX-99.1) covering 2Q 2026 results and financial condition.
Ticker impact
Progyny reported 2Q 2026 revenue of $350.5M, gross margin expansion to 25.5%, and adjusted EBITDA of $62.1M.
Likely positive bias for the stock versus prior quarter expectations, with upside sensitivity to continued renewal risk reduction and selling-season demand.
The filing discloses multiple directionally favorable operating metrics (revenue growth, margin expansion, higher net income) plus capital return activity and no debt, which are typically market-moving for earnings-driven names.
Market effects
Reinforces demand strength and margin expansion dynamics in women’s health and family-building services, potentially supporting peer sentiment.
Primarily US-listed healthcare services sentiment; limited direct regional spillover beyond Nasdaq small/mid-cap growth.
Low global macro linkage; mostly company-specific fundamentals and capital return.
Counterpoint
Operating cash flow was lower year over year ($50.4M vs $55.5M), so the quality of earnings and working-capital timing may temper enthusiasm.
Key entities
- companyProgyny, Inc.
Women’s health and family-building solutions provider reporting 2Q 2026 results and buyback activity.
- executivePete Anevski
CEO quoted on member engagement, selling-season momentum, and renewal risk reduction.
- executiveMark Livingston
CFO quoted on topline growth, gross margin expansion, and cash flow conversion.
